Home/Pipeline/PredicineHEME™

PredicineHEME™

Hematologic Malignancies

CommercialActive

Key Facts

Indication

Hematologic Malignancies

Phase

Commercial

Status

Active

Company

Predicine

About Predicine

Predicine is a private, commercial-stage diagnostics company advancing a next-generation liquid biopsy platform. Its core technology, GeneRADAR, uniquely profiles both DNA and RNA from blood and urine, aiming for more accurate and holistic cancer biomarker detection. The company provides a suite of assay services (e.g., PredicineCARE™, PredicineBEACON™) and partners with biopharma firms to support global clinical trials from its CLIA/CAP labs in the US and China. Predicine is positioned in the high-growth liquid biopsy market, competing on its dual DNA/RNA analysis and urine-based capabilities.

View full company profile

Therapeutic Areas

Oncology

Other Hematologic Malignancies Drugs

Drug	Company	Phase	Status
CER-T Cell Platform	CERo Therapeutics	Pre-clinical	Research & Development
Not Specified (Hematologic Malignancies)	AbelZeta Pharma	Clinical	Active
Orca-T	Bristol Myers Squibb	Phase 3	Active
NK‑Thera	Vectorite Biomedical	Phase 1/2	Active
Trichostatin A (TSA)	Vanda Pharmaceuticals	Development	Active
DARIC-NK Program	Coeptis Therapeutics	Preclinical	Lead Optimization
TSC-102-A01	TScan Therapeutics	Preclinical	IND Cleared by FDA
TSC-102-A03	TScan Therapeutics	Preclinical	IND Cleared by FDA
LBL-007	LakeShore Biopharma	Phase 1/2	Active